title: Human hepatic metabolism of the anxiolytic agent, RWJ-51521--API-MS/MS identification of metabolites.
abstract: The In vitro metabolism of the anxiolytic agent, RWJ-51521 was conducted after incubation with human hepatic S9 fraction in the presence of an NADPH-generating system. Unchanged RWJ-51521 (30% of the sample) and a total of 11 metabolites were profiled, quantified, and tentatively identified on the basis of API (ionspray)-MS/MS data. The 4 proposed metabolic pathways for RWJ-51521 are: (1) N/O-dealkylation, (2) phenylhydroxylation, (3) pyrido-oxidation, and (4) dehydration. Pathway 1 formed 2 major and 3 minor N/O-desalkyl metabolites (M1 & M3, 50%) and in conjunction with pathway 4, formed 2 moderate dehydrated metabolites (M4 & M5, 14%). Pathways 2 and 3 alone, and in conjunction with pathway 4, produced 4 minor metabolites (each < or =2%). RWJ-51521 is extensively metabolized in human hepatic S9 fraction.
authors.affiliation: Johnson & Johnson Pharmaceutical Research & Development, LLC, Spring House, PA 19477, USA.
authors.forename: W N
authors.initials: WN
authors.lastname: Wu
authors.forename: L A
authors.initials: LA
authors.lastname: McKown
authors.forename: A B
authors.initials: AB
authors.lastname: Reitz
mesh_terms: D000577:Amides / Q000378:metabolism*; D014151:Anti-Anxiety Agents / Q000032:analysis / Q000378:metabolism*; D001388:Aziridines; D001562:Benzimidazoles / Q000032:analysis / Q000378:metabolism*; D006801:Humans; D008099:Liver / Q000378:metabolism*; D013058:Mass Spectrometry / Q000379:methods; D021241:Spectrometry, Mass, Electrospray Ionization / Q000379:methods*
chemical_list: C501044:7-fluoro-1,2-dihydro-5-(2-(N-methyl-N-(2-methoxyethyl)amino)ethyl)-3-oxo-N-(2-fluorophenyl)pyrido(1,2-a)benzimidazole-4-carboxamide hydrochloride; D000577:Amides; D014151:Anti-Anxiety Agents; D001388:Aziridines; D001562:Benzimidazoles; C071269:6-N-aziridinyl-3-hydrox-7-methyl-2,3-dihydro-1H-pyrrolo(1,2-a)benzimidazole-5,8-dione 3-acetate
references.citation: J Pharmacol Exp Ther. 2002 Nov;303(2):777-90
references.pmid: 12388665
references.citation: J Med Chem. 1995 Jan 6;38(1):16-20
references.pmid: 7837226
references.citation: Bioorg Med Chem Lett. 1999 Jun 7;9(11):1547-52
references.pmid: 10386933
references.citation: Bioorg Med Chem Lett. 2002 Sep 2;12(17):2381-6
references.pmid: 12161138
references.citation: J Pharm Biomed Anal. 2003 Feb 5;31(1):95-102
references.pmid: 12560053
references.citation: J Pharm Pharmacol. 2003 Aug;55(8):1099-105
references.pmid: 12956899
references.citation: Prog Med Chem. 1999;36:169-200
references.pmid: 10818673